Linc01234 promotes cell proliferation and metastasis in oral squamous cell carcinoma via miR-433/PAK4 axis
Background: Increasing studies have demonstrated that long non-coding RNAs (lncRNAs) play an important role in tumor progression. However, the potential biological functions and clinical importance of Linc01234 in oral squamous cell carcinoma (OSCC) remain unclear.
Methods: We evaluated the expression profile and prognostic value of Linc01234 in OSCC tissues by RT-qPCR. Then, functional in vitro experiments were performed to investigate the effects of Linc01234 on tumor growth, migration and invasion in OSCC. Mechanistically, RT-qPCR, bioinformatic analysis and dual luciferase reporter assays were performed to identify a competitive endogenous RNA (ceRNA) mechanism involving Linc01234, miR-433-3p and PAK4.
Results: We found that Linc01234 was clearly upregulated in OSCC tissues and cell lines, and its level was positively associated with T stage, lymph node metastasis, differentiation and poor prognosis of patients with OSCC. Our results shown that Linc01234 inhibited cell proliferation and metastatic abilities in CAL27 and SCC25 cells following its knockdown. Mechanistic analysis indicated that Linc01234 may act as a ceRNA (competing endogenous RNA) of miR-433-3p to relieve the repressive effect of miR-433-3p on its target PAK4.
Conclusions: Our results indicated that Linc01234 promotes OSCC progression through the Linc01234/miR-433/PAK4 axis and might be a potential therapeutic target for OSCC.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Posted 16 Jan, 2020
On 10 Feb, 2020
On 14 Jan, 2020
On 14 Jan, 2020
On 07 Jan, 2020
On 07 Jan, 2020
On 17 Dec, 2019
On 13 Dec, 2019
On 12 Dec, 2019
On 12 Dec, 2019
On 09 Dec, 2019
Received 05 Dec, 2019
Invitations sent on 02 Dec, 2019
On 02 Dec, 2019
On 11 Nov, 2019
On 11 Nov, 2019
On 11 Nov, 2019
On 15 Oct, 2019
Received 13 Oct, 2019
On 01 Oct, 2019
Received 01 Oct, 2019
On 28 Sep, 2019
Invitations sent on 14 Aug, 2019
On 07 Aug, 2019
On 24 Jul, 2019
On 23 Jul, 2019
On 19 Jul, 2019
Linc01234 promotes cell proliferation and metastasis in oral squamous cell carcinoma via miR-433/PAK4 axis
Posted 16 Jan, 2020
On 10 Feb, 2020
On 14 Jan, 2020
On 14 Jan, 2020
On 07 Jan, 2020
On 07 Jan, 2020
On 17 Dec, 2019
On 13 Dec, 2019
On 12 Dec, 2019
On 12 Dec, 2019
On 09 Dec, 2019
Received 05 Dec, 2019
Invitations sent on 02 Dec, 2019
On 02 Dec, 2019
On 11 Nov, 2019
On 11 Nov, 2019
On 11 Nov, 2019
On 15 Oct, 2019
Received 13 Oct, 2019
On 01 Oct, 2019
Received 01 Oct, 2019
On 28 Sep, 2019
Invitations sent on 14 Aug, 2019
On 07 Aug, 2019
On 24 Jul, 2019
On 23 Jul, 2019
On 19 Jul, 2019
Background: Increasing studies have demonstrated that long non-coding RNAs (lncRNAs) play an important role in tumor progression. However, the potential biological functions and clinical importance of Linc01234 in oral squamous cell carcinoma (OSCC) remain unclear.
Methods: We evaluated the expression profile and prognostic value of Linc01234 in OSCC tissues by RT-qPCR. Then, functional in vitro experiments were performed to investigate the effects of Linc01234 on tumor growth, migration and invasion in OSCC. Mechanistically, RT-qPCR, bioinformatic analysis and dual luciferase reporter assays were performed to identify a competitive endogenous RNA (ceRNA) mechanism involving Linc01234, miR-433-3p and PAK4.
Results: We found that Linc01234 was clearly upregulated in OSCC tissues and cell lines, and its level was positively associated with T stage, lymph node metastasis, differentiation and poor prognosis of patients with OSCC. Our results shown that Linc01234 inhibited cell proliferation and metastatic abilities in CAL27 and SCC25 cells following its knockdown. Mechanistic analysis indicated that Linc01234 may act as a ceRNA (competing endogenous RNA) of miR-433-3p to relieve the repressive effect of miR-433-3p on its target PAK4.
Conclusions: Our results indicated that Linc01234 promotes OSCC progression through the Linc01234/miR-433/PAK4 axis and might be a potential therapeutic target for OSCC.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5